

Imugene

On track for anti-tumour vaccine trial in H215

On track for Phase Ib

Pharma & biotech

Imugene is on track to initiate a Phase Ib/II trial of its gastric (stomach) cancer therapeutic vaccine, HER-Vaxx, in H215. HER-Vaxx aims to replicate and improve on the combination of two proven therapeutic antibodies, Herceptin and Perjeta (Roche), which significantly improves survival in breast cancer and may do so in gastric cancer. Global gastric cancer incidence is 934,000 cases with few current therapeutic options and low survival. Imugene raised A\$3.6m in H214, which gives it sufficient funds to initiate the Phase Ib/II trial, with the aim of gaining a major pharma deal following Phase II data in the buoyant cancer immunotherapy area.

| Year end | Revenue (A\$m) | PBT* (A\$m) | EPS* (c) | DPS (c) | P/E (x) | Yield (%) |
|----------|----------------|-------------|----------|---------|---------|-----------|
| 06/14 | 0.5 | (0.4) | (0.1) | 0.0 | N/A | N/A |
| 06/15e | 0.3 | (2.3) | (0.2) | 0.0 | N/A | N/A |
| 06/16e | 0.0 | (2.8) | (0.2) | 0.0 | N/A | N/A |
| 06/17e | 0.0 | (3.1) | (0.2) | 0.0 | N/A | N/A |

Note: *PBT and EPS are normalised, excluding intangible amortisation, exceptional items and share-based payments.

Antibodies that target HER2 boost cancer survival

HER-Vaxx comprises three linked HER2 peptides (protein fragments) delivered in a flu-based virosome. In the Phase I in 10 breast cancer patients, 8 developed antibodies against HER2, a proven cancer target. The marketed anti-HER2 therapeutic antibodies Herceptin and Perjeta improve overall survival by 34% (hazard ratio 0.66) in breast cancer. HER2 is overexpressed in up to 20% of gastric cancers and Herceptin improves survival by 2.5 months (13.5 months vs 11.0 months chemotherapy control). A potent vaccine would be a major advance in gastric cancer therapy, as the disease is poorly served by other therapeutic options.

Preparations well advanced for Gastric cancer trial

Since we [initiated](#) coverage in November 2014, Imugene has made good progress in preparing for the 18-patient Phase Ib trial due to commence in H215: preclinical testing confirmed in December that HER-Vaxx fusion peptide antigens are highly immunogenic, generating high levels of HER-2-specific antibodies, and that the generated antibodies recognise native HER-2 proteins; the trial protocol was finalised in December; and a CRO will be appointed shortly. Results are imminent from preclinical trials that aim to identify new insights into the HER-Vaxx technology and to generate data to support an IND application to the US FDA. The Phase Ib will be followed by a randomised Phase II trial in 68 gastric cancer patients.

Weaker Australian dollar boosts valuation

Due to the continued weakness of the A\$ we lower our long-term exchange rate assumption to A\$0.80/US\$ (previously A\$0.88/US\$), which increases our risk-adjusted NPV to A\$52.6 (previously A\$49.3m), equivalent to 4.1c/share. Our valuation assumes a 20% likelihood of success and includes a A\$25m deal upfront after Phase II (at a 30% probability) and a A\$50m Phase III success milestone at a 20% probability. The immunotherapy area has recently seen sizeable overall deal values including large milestones. Cash was A\$3.0m on 31 December 2014.

13 April 2015

Price **A\$0.01**

Market cap **A\$13m**

A\$0.80/US\$

Cash (A\$m) at 31 December 2014 A\$3.0m

Shares in issue 1,329.9m


Free float 58%

Code IMU

Primary exchange ASX

Secondary exchange N/A

Share price performance



% 1m 3m 12m

Abs 0.0 (10.0) (18.2)

Rel (local) (2.4) (17.5) (24.5)

52-week high/low A\$0.02 A\$0.01

Business description

Imugene restructured into a cancer vaccine business with the acquisition of HER-Vaxx, a proprietary HER2 +ve cancer vaccine, in December 2013. A Phase Ib dose study is planned in gastric cancer starting in H215 with a randomised Phase II follow-on study in 68 patients.

Next events

File IND application Q215

Phase Ib start H215

FY15 results Q315

Analysts

Dr Dennis Hulme +61 (0)2 9258 1161

Dr John Savin MBA +44 (0)20 3077 5735

healthcare@edisongroup.com

[Edison profile page](#)

Imugene is a research client of Edison Investment Research Limited

Valuation

We have calculated a discounted, risk-adjusted cash flow valuation using the key assumptions in Exhibit 1. These are then applied to the market data in Exhibit 2 to give potential peak sales of about US\$725m.

| Exhibit 1: Valuation parameters | |
|--|--------|
| Key model assumptions | Value |
| HER2+ percentage of diagnosed patients ¹ | 20% |
| Percentage eligible for therapy | 75% |
| US price (US\$) per year | 75,000 |
| Royalty percentage from partner | 12% |
| Share of IMU revenue payable to BSFE until 2030 (based on royalties and milestones received from partners) | 18% |
| Upfront payment in 2019 (A\$m) | 25 |

Source: Edison Investment Research

| Exhibit 2: Market data and non-adjusted cash flow in 2030 | | | | | | |
|--|----------------|----------------|--------|----------------|------------------|-------------|
| Market (US\$ unless otherwise stated) | Cases | Eligible | Uptake | Number treated | Price (US\$'000) | Value (\$m) |
| US | 22,200 | 3,330 | 25% | 833 | 75.0 | 62 |
| Western EU | 62,240 | 9,336 | 40% | 3,734 | 60.0 | 224 |
| Eastern EU | 18,360 | 2,754 | 25% | 689 | 37.5 | 26 |
| Eastern Europe and Russia | 59,000 | 8,850 | 25% | 2,213 | 37.5 | 83 |
| Japan | 102,740 | 15,411 | 15% | 2,312 | 112.5 | 260 |
| China | 382,940 | 57,441 | 5% | 2,872 | 18.8 | 54 |
| E Asia | 37,360 | 5,604 | 2% | 112 | 18.8 | 2 |
| other | 249,160 | 37,374 | 2% | 747 | 18.8 | 14 |
| Total | 934,000 | 140,100 | | | | 725 |
| Sales in A\$ | Rate | US\$0.80/A\$ | | | | A\$907 |
| Royalty from partner to Imugene | Rate | 12% | | | | A\$109 |
| Share of Imugene income paid to BSFE (18%) | | | | | | (A\$20) |
| Potential Imugene profit after A\$2m admin costs and 30% tax in 2030 | | | | | | A\$61 |

Source: Market data references,^{2,3} Edison Investment Research

Pricing and market share will vary according to patent strength, competition and the level of healthcare funding and infrastructure at that time. A US price of \$75,000 per year is assumed, with patients taking therapy for a year on average. Prices are usually lower in Europe, higher in Japan and reduced elsewhere. There seems to be no Japanese patent, so a lower share is used there.

Our standard practice is to assume a probability of success between 10% and 20% for Phase I trials. We apply a 20% probability for HER-Vaxx, at the top of this range, in view of the safety and tolerability shown in the Phase I trial, and the fact that the HER-2 epitopes included in the vaccine have been validated as targets by the efficacy of the approved monoclonal therapeutics Herceptin (trastuzumab, Roche) and Perjeta (pertuzumab, Roche).

| Exhibit 3: Valuation table (based on Exhibits 1 and 2) | | |
|--|-------------|----------------------|
| Discounted cash flow stream | Probability | Present value (A\$m) |
| Value of net cash flow until 2032 (excluding upfront payments) | 20% | 46.5 |
| Value of 2019 upfront and 2023 milestone (net of royalties) | 30% | 6.1 |
| Total value | | 52.6 |

Source: Edison Investment Research

The assumed upfront of A\$25m is generally comparable with Phase II deals, although no specific antibody-based vaccine benchmarks can be ascertained. An approval milestone of A\$50m is assumed at the technical probability of 20%. We assume that 18% of HER-Vaxx revenue received

1 Jørgensen, J. T. Role of human EGFR 2 in gastric cancer. *World J. Gastroenterol.* 20, 4526–35 (2014).

2 Jemal, A. et al. Global cancer statistics. *CA. Cancer J. Clin.* 61, 69–90.

3 Ferlay, J. et al. Cancer incidence and mortality patterns in Europe. *Eur. J. Cancer* 49, 1374–403 (2013).

by Imugene (including upfront, milestone and royalty payments) is paid to BSFE,⁴ the original owners of the HER-Vaxx IP. A 30% Australian tax rate is applied from 2026. This gives an indicative value (Exhibit 3) of A\$53m (4.1c/share); this is not a price target.

Financials: Cash to fund Phase II

Imugene obtained the main HER-Vaxx intellectual property in December 2013 through the acquisition of Biolife Science Qld for A\$4.5m in equity (300m shares at A\$0.015 each). Imugene is currently seeking to divest its previous focus, a drug delivery technology (Linguet), which has a carrying value of A\$0.3m. The other intangible asset on the balance sheet as of 31 December was HER-Vaxx, which is valued at A\$6.6m.

The operating loss in H115 was A\$1.1m, compared with our previous forecast of a loss of A\$1.4m for the full year. We have increased our forecast spend on both R&D and administrative costs, and now forecast operating losses of A\$2.4m in FY15 and A\$2.8m in FY16.

Imugene raised A\$2.6m in FY14 (to 30 June 2014) to fund initial HER-Vaxx development and preparation for the clinical trial. Revenue in FY14 comprised an R&D tax rebate of A\$0.5m and some interest income; an R&D rebate payment of A\$0.23m was received in February 2015. As most Phase Ib/II costs will be outside Australia, no further R&D tax rebates have been assumed. In November and December 2014, the company raised a further A\$3.6m (A\$3.3m after costs) in a placement and share purchase plan (358m shares issued at A\$0.01/share). Cash was A\$3.0m on 31 December 2014. The current funding is sufficient to initiate the Phase Ib/II trial, but further funding will be needed. Illustrative long-term debt of A\$1m in 2016e and A\$4m in 2017e is included to represent this. Financial projections are shown in Exhibit 4.

Sensitivities

The major potential value inflection point for investors is that the Phase II produces strong data to enable a big pharma licensing deal (with an upfront fee) that covers Phase III costs. Prior to then, potential partners may also take notice if the Phase Ib shows evidence of potential efficacy (cellular plus humoral immune response, generation of anti-HER2 antibodies). In October 2014 BMS paid US\$50M for an option to acquire Austrian biotech F-star Alpha, and its Phase I-ready bi-specific antibody drug targeting HER2-positive cancers; total deal value could reach US\$475m if the drug is approved in the US and Europe. The double antibody action that HER-Vaxx aims to replicate, and perhaps improve on, is proven in breast cancer. In Phase I, in a non-target population, HER-Vaxx generated antibody responses against all three peptides. These are strong positive indicators.

Uncertainties arise as it is unclear how effectively HER-Vaxx can be combined with chemotherapy in Phase II as vaccine responses take time to develop and chemotherapy could potentially inhibit the immune response. On the other hand, some chemotherapy agents, including cisplatin, have been shown to stimulate the immune system.⁵ The Phase I trial showed that patients treated with HER-Vaxx produced antibodies against HER2, but we do not yet know how the concentration of antibodies compares with the levels seen in patients treated with Herceptin or Perjeta. As the vaccine aims to stimulate an immune response against the normal HER2 protein that the immune system usually tolerates as “self”, the amount, potency and duration of anti-HER2 antibody production will be an important indicator of likely efficacy.

Royalties are hard to forecast since most gastric cancer patients are in Asia and therapeutic options may broaden over the next eight years as other candidate trials report data.

4 Biolife Science Forschungs und Entwicklungsges mbHH (BSFE, a company incorporated in Austria).

5 Biasi et al. Cisplatin induced antitumor immunomodulation. *Clin Cancer Res*; 20(21); 5384–91 (2014).

Exhibit 4: Financial summary

| A\$'000s | 2014 | 2015e | 2016e | 2017e |
|--|---------|---------|---------|---------|
| Year end 31 June | IFRS | IFRS | IFRS | IFRS |
| PROFIT & LOSS | | | | |
| Revenue | 511 | 343 | 0 | 0 |
| Cost of Sales | 0 | 0 | 0 | 0 |
| Gross Profit | 511 | 343 | 0 | 0 |
| EBITDA | (386) | (2,382) | (2,825) | (3,125) |
| Operating Profit (before GW and except.) | (386) | (2,382) | (2,825) | (3,125) |
| Intangible Amortisation | (1,691) | 0 | 0 | 0 |
| Exceptionals, share based payments | (66) | (75) | (75) | (75) |
| Other | 0 | 0 | 0 | 0 |
| Operating Profit | (2,143) | (2,457) | (2,900) | (3,200) |
| Net Interest | 27 | 50 | 0 | 0 |
| Profit Before Tax (norm) | (359) | (2,332) | (2,825) | (3,125) |
| Profit Before Tax (FRS 3) | (2,116) | (2,407) | (2,900) | (3,200) |
| Tax | 0 | 0 | 0 | 0 |
| Profit After Tax (norm) | (359) | (2,332) | (2,825) | (3,125) |
| Profit After Tax (FRS 3) | (2,116) | (2,407) | (2,900) | (3,200) |
| Average Number of Shares Outstanding (m) | 689.2 | 1,126.6 | 1,329.9 | 1,329.9 |
| EPS - normalised (c) | (0.05) | (0.21) | (0.21) | (0.23) |
| EPS - FRS 3 (c) | (0.31) | (0.21) | (0.22) | (0.24) |
| Dividend per share (c) | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross Margin (%) | N/A | N/A | N/A | N/A |
| EBITDA Margin (%) | N/A | N/A | N/A | N/A |
| Operating Margin (before GW and except.) (%) | N/A | N/A | N/A | N/A |
| BALANCE SHEET | | | | |
| Fixed Assets | 6,874 | 6,874 | 6,874 | 6,874 |
| Intangible Assets | 6,874 | 6,874 | 6,874 | 6,874 |
| Tangible Assets | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 0 | 0 |
| Current Assets | 1,758 | 2,306 | 406 | 281 |
| Stocks | 0 | 0 | 0 | 0 |
| Debtors | 15 | 15 | 15 | 15 |
| Cash | 1,223 | 2,280 | 380 | 255 |
| Other | 520 | 11 | 11 | 11 |
| Current Liabilities | (697) | (322) | (247) | (247) |
| Creditors | (247) | (247) | (247) | (247) |
| Current loans | 0 | 0 | 0 | 0 |
| Other inc HER-Vaxx IP creditor | (450) | (75) | 0 | 0 |
| Long Term Liabilities | (1,202) | (1,127) | (3,127) | (5,127) |
| Long term debt | 0 | 0 | (1,000) | (4,000) |
| HER-Vaxx IP Creditor | (75) | 0 | 0 | 0 |
| Other long term liabilities | (1,127) | (1,127) | (2,127) | (1,127) |
| Net Assets | 6,732 | 7,730 | 3,905 | 1,780 |
| CASH FLOW | | | | |
| Operating Cash Flow | (1,171) | (2,323) | (2,900) | (3,125) |
| Net Interest | 27 | 50 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 |
| Capex | (600) | 0 | 0 | 0 |
| Acquisitions/disposals | 6 | 0 | 0 | 0 |
| Financing | 2,396 | 3,600 | 0 | 0 |
| Dividends | 0 | 0 | 0 | 0 |
| Other funding | 0 | (270) | 0 | 0 |
| Net Cash Flow (ex-debt movements) | 657 | 1,057 | (2,900) | (3,125) |
| Opening net debt/(cash) | (566) | (1,223) | (2,280) | 620 |
| HP finance leases initiated | 0 | 0 | 0 | 0 |
| Other | 0 | (0) | 0 | 0 |
| Closing net debt/(cash) | (1,223) | (2,280) | 620 | 3,745 |

Source: Imugene reports, Edison Investment Research. Note: FY13 is omitted as it is not relevant to the current business.

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2015 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Imugene and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2015. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.